`

Tagged: Phase 1

A translational medicine program includes the adoption of biomarkers to mitigate Phase I and II clinical risks, identify patient subpopulations, facilitate decision-making, and accelerate the release of a drug on the market.

February 16th, 2023 | Phase 1

BBCR’s epigenetic expert, Dr. Claudio Carini, has been a pioneer in epigenetics leading the effort of major pharmaceutical companies. BBCR helps to bridge the gap between pre-clinical and early clinical development. Translational medicine is a bridge between pre-clinical and early clinical development (from bench to bedside), creating the foundation for precision medicine in late clinical […]

BBCR uses innovative approaches to de-risk your product development. For our clients interested in Proof of Mechanism and Proof of Concept – PoM and PoC – Our team has the expertise to ensure successful product development at any stage of development.

November 28th, 2022 | Phase 1
PoM and PoC Services Boston Biotech Clinical Research

The BBCR team designs Proof of Concept (PoC) Trials and Proof of Mechanism (PoM) studies with the drug clinical plan and regulatory strategy in mind. Proof of Mechanism (PoM) Usually in Healthy Volunteers, Phase 1 study Essential for the selection of appropriate dose for PoC, disease model and biomarkers Investigate drug concentration at the target […]

BBCR has extensive experience in early development Phase 1 and 2, from pre-clinical to pre-IND. BBCR’s early drug development experience includes the development of clinical strategy and plan, including target product profiles and clinical protocols.

June 30th, 2022 | Phase 1

Boston Biotech Clinical Research works with biotech, pharmaceutical, device companies and investors to streamline the clinical trial process and strategy. Our experienced team helps each client reach their specific goals by customizing a clinical and regulatory road map of simplified programs and streamlined protocols to meet our clients’ requirements.  

Depending on your project goals, BBCR can work with you to design cost-effective early clinical studies that hold potential for reducing Phase III failures.

March 3rd, 2021 | Phase 1

Expertise in integration of in vitro and in vivo analysis during early clinical research is a critical development milestone for efficient candidate development. In addition, the BBCR team guides in identifying the right target, the right biomarker, the right safety, the right patients and the right commercial potential. BBCR can assist clients across a variety […]

Pin It on Pinterest